News Curasight A/S

Equities

CURAS

DK0061295797

End-of-day quote NORDIC GROWTH MARKET Other stock markets 23:00:00 29/04/2024 BST			5-day change	1st Jan Change
10.2 ^DKK	-.--%		+1.49%	-42.54%

04-16	Curasight A/S Announces Approval of Clinical Trial Application for Phase 2 Trial with uTRACE in Prostate Cancer Patients	CI
04-12	Curasight A/S Announces Board Changes	CI

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

BioStock: Curasight gets green light from EMA in phase II prostate cancer trial	04-22	AQ
Curasight announces approval of clinical trial application (CTA) for phase 2 trial with uTRACE[®] in prostate cancer patients	04-16	AQ
Curasight A/S Announces Approval of Clinical Trial Application for Phase 2 Trial with uTRACE in Prostate Cancer Patients	04-16	CI
Curasight announces change in the Board of Directors	04-12	AQ
Curasight A/S Announces Board Changes	04-12	CI
BioStock: Curasight cancels rights issue and evaluates alternative financing	03-13	AQ
Curasight not to proceed with rights issue; evaluating alternative financing opportunities	03-11	AQ
Notice of Annual General Meeting 2024	03-06	AQ
The subscription period in Curasight's rights issue begins today	02-23	AQ
Curasight publishes information memorandum in connection with forthcoming rights issue	02-22	AQ
Annual Report for the fiscal year 2023	02-22	AQ
Year-end report October - December 2023	02-22	AQ
Curasight A/S Reports Earnings Results for the Full Year Ended December 31, 2023	02-22	CI
Curasight A/S Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	02-22	CI
BioStock: Curasight to accelerate therapeutic strategy by DKK 51.2 million capital raise	02-19	AQ
Curasight resolves on a rights issue of up to DKK 51.2 million to accelerate its therapeutic strategy	02-13	PR
Curasight resolves on a rights issue of up to DKK 51.2 million to accelerate its therapeutic strategy	02-13	AQ
Curasight announces acceleration of therapeutic strategy to strengthen position as a radiopharmaceutical theranostic company	02-13	AQ
Curasight A/S Announces Acceleration of Therapeutic Strategy to Strengthen Position as A Radiopharmaceutical Theranostic Company	02-13	CI
BioStock: Curasight gets first milestone payment from Curium	02-02	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Curasight A/S

Equities

CURAS

DK0061295797

Summary

Filters